What’s Ahead for 2024?
As we dive into 2024, we asked our ADVI experts what they think the most compelling or anticipated healthcare issues will be this year. From a continued emphasis on the Inflation Reduction Act (IRA) to upcoming launches in cell and gene therapy, challenging payer dynamics, greater challenges for patient access, and cell and gene therapy access model updates, there is much to look forward to this year.
Peter Kardel, chief data scientist with the ADVI Strategic Analytics, Value and Economics team, discusses anticipated advancements in the health economic outcomes research (HEOR) space relating to new medications hitting the market and potential savings opportunities.
Learn More
Stay ahead of the curve this year. Get in touch today to gain expert insights and strategic counsel on the evolving healthcare landscape.
CEO insights
Related articles
Real analysis from people who’ve been there
Medicare Negotiation Program Deselection: Analysis of Previously Deselected Drugs and Likely Fall 2026 Targets
Authored by Allison Schneider, MHA, and Lindsay Bealor Greenleaf, JD, MBA Under the Inflation Reduction Act, drugs selected for the …
Exclusive Webinar: Unpacking the Future of U.S. Drug Pricing Policy
Gain immediate access to actionable insights from CMS and ADVI Health policy leaders. From the Medicare Drug Price Negotiation Program …
Analysis of 340B modifier usage in Medicare Part B claims
Analysis of Part B Claims from January 2025 through June 2026 Prepared By:Johanna Celli, Pete Kardel, Caitlin Sheetz, ADVI Health’s …
The Growing Relevance of HEOR: Turning Complex Healthcare Questions Into Actionable Evidence
For the first time, ISPOR added “Relevance of HEOR: Demonstrating the Field’s Vital Role in Health” to its Top 10 …
ADVI Health Accelerates Insights with Monthly Medicare Data
ADVI Health now has access to 100% of Medicare Parts A, B, and D research files with monthly availability – …
Why Clinical Laboratories Should Consider Weighing In on CMS and CDC’s New CLIA Request for Information
An opportunity for laboratories to help shape the future of CLIA regulation On July 16, 2026, the Centers for Medicare …
RAND/UCLA Modified Delphi Panels
ADVI Health partners with pharmaceutical and biotech organizations to advance their evidence generation and market access strategies. We support complex research questions through primary research (e.g., …
Caitlin Sheetz, MPH
June 23, 2026
The MolDX Technical Assessment: How to Move Your Test from “Not Successful” to Medicare Coverage Success
In the laboratory space, the MolDX Technical Assessment (TA) is often the moment where the gap between “a great test” …
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.